Home Conference Coverage ASH Conference Coverage

ASH Conference Coverage

Liso-cel Versus Standard of Care as Second-Line Therapy for Relapsed/Refractory LBCL

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

Tisa-Cel Found Noninferior to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL

ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma

Black Patients Are Severely Under-Represented in Pivotal CAR T-Cell Clinical Trials

High Complete Response Rates With Magrolimab and Azacitidine Plus Venetoclax in Newly Diagnosed, High-Risk...

Polycythemia Vera Patients Have Improved Hematocrit Response With Rusfertide

Axicabtagene Ciloleucel Produces High Complete Response Rates in Large B-Cell Lymphoma

Anti-BCMA CAR T-Cell Therapy CT103A Provides Rapid, Durable Responses

CAR T-Cell Therapy Recipients May Have Higher Unplanned Use of Healthcare Resources

Load more
Subscribe to RSS